Edge Therapeutics Company Profile (NASDAQ:EDGE)

Analyst Ratings

Consensus Ratings for Edge Therapeutics (NASDAQ:EDGE) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.50 (127.50% upside)

Analysts' Ratings History for Edge Therapeutics (NASDAQ:EDGE)
Show:
DateFirmActionRatingPrice TargetActions
5/9/2016Credit Suisse Group AGLower Price TargetOutperform$19.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2016Leerink SwannReiterated RatingOutperform$27.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$34.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/26/2015GuggenheimInitiated CoverageBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Edge Therapeutics (NASDAQ:EDGE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/3/2016        
5/3/2016($0.34)($0.32)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/8/2016Q4($0.32)($0.30)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2015Q315($0.23)($7.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Edge Therapeutics (NASDAQ:EDGE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.42)($0.42)($0.42)
Q2 20161($0.43)($0.43)($0.43)
Q3 20161($0.46)($0.46)($0.46)
Q4 20161($0.48)($0.48)($0.48)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Edge Therapeutics (NASDAQ:EDGE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Edge Therapeutics (NASDAQ:EDGE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/11/2016James HealyDirectorBuy541,343$7.30$3,951,803.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015Andrew J. EinhornCFOBuy45,000$11.00$495,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015James HealyDirectorBuy450,000$11.00$4,950,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Edge Therapeutics (NASDAQ:EDGE)
DateHeadline
07/27/16 06:58 AMEdge Therapeutics to Host Conference Call on August 3, 2016 to Discuss Second Quarter Financial Results - [at noodls] - BERKELEY HEIGHTS, N.J., July 27, 2016 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, ...
07/25/16 08:28 AMFDA Lifts Clinical Hold On CGF166
07/20/16 04:58 PMEdge Therapeutics Incorporated (NASDAQ:EDGE) Shorted Shares Increased 44.4% After Market Selling - Consumer Eagle
07/17/16 03:28 PMNext Weeks Broker Price Targets For Edge Therapeutics, Inc. (NASDAQ:EDGE) - Fiscal Standard
07/15/16 10:47 AMEdge Therapeutics Incorporated (NASDAQ:EDGE) Sellers Covered 5.26% of Their Shorts - Consumer Eagle
07/15/16 10:47 AMHow Analysts Rated Edge Therapeutics Inc (NASDAQ:EDGE) Last Week? - Consumer Eagle
07/13/16 09:00 PM$17M supports five genomic application projects
07/13/16 07:29 AMShares Losing Ground for the Month; Investor Alert on Edge Therapeutics, Inc. (:EDGE) - Engelwood Daily
07/13/16 07:29 AMBroker Outlook For Edge Therapeutics, Inc. (NASDAQ:EDGE) - Fiscal Standard
07/11/16 03:46 PMNew genomic application projects to spur innovation across many Canadian sectors
07/11/16 08:33 AMStock on the Rise for the Quarter: Edge Therapeutics, Inc. (:EDGE) - Engelwood Daily
07/10/16 08:17 AMEdge Therapeutics Incorporated (NASDAQ:EDGE) Shorts Decreased by 5.26% After Short Covering - Press Telegraph
07/09/16 07:15 AMNew Broker Ratings For Edge Therapeutics, Inc. (NASDAQ:EDGE) - FTSE News
07/09/16 07:15 AMIncreased Volatility on Shares of: Edge Therapeutics, Inc. (:EDGE) - Engelwood Daily
07/08/16 07:39 AMStock Futures Edge Higher Ahead of June Jobs Report - TheStreet.com
07/07/16 08:56 PMAgile Therapeutics' (AGRX) Latest Hire Should Boost Key Ortho Evra Launch - Noble Financial - StreetInsider.com
07/07/16 07:12 AMEuropean ADRs Edge Lower as Banking Losses Offset Pharma Gains - Nasdaq
07/07/16 07:12 AMEdge Therapeutics Incorporated (NASDAQ:EDGE) Shorted Shares Decreased By 5.26% - Press Telegraph
07/07/16 07:12 AMIncreased Volatility Watch for: Edge Therapeutics, Inc. (:EDGE) - Engelwood Daily
07/07/16 07:12 AMBRIEF-Edge Therapeutics appoints Harry Sacks vice president, clinical development - Reuters
07/07/16 07:12 AMEdge Therapeutics Announces Appointment of Harry J. Sacks, MD, FAAP, as Vice President, Clinical Development - Yahoo Finance
07/06/16 03:51 PMEdge Therapeutics Announces Appointment of Harry J. Sacks, M.D., FAAP, as Vice President, Clinical Development - [at noodls] - BERKELEY HEIGHTS, N.J., July 06, 2016 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, ...
07/05/16 08:29 AMTakeda and TiGenix Enter into Licensing Agreement for Ex-U.S. rights to Cx601 for the Treatment of Complex Perianal ... - GlobeNewswire (press release)
07/04/16 03:29 PMBroker Outlook For The Week Ahead Edge Therapeutics, Inc. (NASDAQ:EDGE) - Fiscal Standard
07/03/16 03:29 PMEuropean ADRs Edge Higher in Friday Trading - Nasdaq
07/01/16 03:47 PMShares Headed Up in Session: Edge Therapeutics, Inc. (:EDGE) - Telanagana Press
06/30/16 09:10 PMAre Analysts Bullish Edge Therapeutics Inc (NASDAQ:EDGE) After Last Week? - Engelwood Daily
06/26/16 08:45 AMEdge Therapeutics Incorporated (NASDAQ:EDGE) Shorts Decreased by 5.26% After Short Covering - Engelwood Daily
06/24/16 03:51 PMJRJR NETWORKS TO HOLD SHAREHOLDER CALL TODAY AT 5 : 30 pm Eastern Time
06/24/16 03:51 PMForm 4 Edge Therapeutics, Inc. For: Jun 21 Filed by: New Leaf Venture Partners, L.L.C.
06/24/16 03:17 PMEDGE THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/24/16 12:10 PMEdge Therapeutics Granted U.S. Patent Covering the Expanded Use of Lead Candidate EG-1962 - [at noodls] - BERKELEY HEIGHTS , N.J., June 24, 2016 - Edge Therapeutics, Inc. (Nasdaq: EDGE), a clinicalstage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening ...
06/24/16 10:31 AMForm 4 Edge Therapeutics, Inc. For: Jun 21 Filed by: New Leaf Venture Partners, LLC - StreetInsider.com
06/23/16 08:47 PMHow Many Edge Therapeutics Inc (NASDAQ:EDGE)'s Analysts Are Bullish? - Engelwood Daily
06/23/16 08:47 PMForm 4 Edge Therapeutics, Inc. For: Jun 21 Filed by: Conti Kurt G - StreetInsider.com
06/23/16 02:42 PMForm 4 Edge Therapeutics, Inc. For: Jun 21 Filed by: BLECH ISAAC - StreetInsider.com
06/23/16 06:51 AMEdge Therapeutics, Inc. (NASDAQ:EDGE) Current Analyst Ratings - Fiscal Standard
06/18/16 08:19 AMRecently Issued Stock Ratings For Edge Therapeutics, Inc. (NASDAQ:EDGE) - Fiscal Standard
06/10/16 03:52 PMWill Edge Therapeutics (EDGE) Continue to Surge Higher? - Nasdaq
06/10/16 11:09 AMEdge Therapeutics’ Chief Accounting and Operations Officer Bert Marchio Receives the New Jersey Tech Council Deal of the Year Award - [at noodls] - MONROE TOWNSHIP, N.J., June 10, 2016 - Edge Therapeutics, Inc. (Nasdaq: EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening ...
06/10/16 08:19 AMWill Edge Therapeutics (EDGE) Continue to Surge Higher?
06/03/16 04:01 PMBroker Watchlist: Edge Therapeutics, Inc. (NASDAQ:EDGE) - Share Trading News
06/02/16 09:50 PMAre Analysts Bearish Edge Therapeutics Inc (NASDAQ:EDGE) After Last Week? - HNN - Are Analysts Bearish Edge Therapeutics Inc (NASDAQ:EDGE) After Last Week?HNNOut of 4 analysts covering Edge Therapeutics (NASDAQ:EDGE), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Edge Therapeutics has been the topic of 4 analyst reports since October 26, 2015 according to StockzIntelligence Inc.and more »
06/02/16 12:03 PMEdge Therapeutics, Inc. :EDGE-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 -
06/02/16 08:11 AMEdge Therapeutics (EDGE) Catches Eye: Stock Soars 19.4% - Nasdaq - Edge Therapeutics (EDGE) Catches Eye: Stock Soars 19.4%NasdaqEdge Therapeutics, IncEDGE was a big mover last session, as the company saw its shares rise over 19% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the ...
06/02/16 08:11 AMCan Edge Therapeutics Inc. (NASDAQ:EDGE) Survive? - Scibility Media - Scibility MediaCan Edge Therapeutics Inc. (NASDAQ:EDGE) Survive?Scibility MediaEdge Therapeutics Inc. (NASDAQ: EDGE) is enjoying some regulatory priorities in the development of aneurysmal subarachnoid hemorrhage (aSAH) treatment EG-1962. The FDA has granted the compound both Fast-Track and Orphan drug designations.Edge Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswire (press release)all 2 news articles »
06/02/16 07:00 AMEdge Therapeutics (EDGE) Catches Eye: Stock Soars 19.4% -
06/02/16 06:45 AMEdge Therapeutics to Present at Upcoming Investor Conferences - [at noodls] - BERKELEY HEIGHTS, N.J., June 02, 2016 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies for the management of acute, ...
05/25/16 11:03 AMBroker Roundup For Edge Therapeutics, Inc. (NASDAQ:EDGE) - Share Trading News - Broker Roundup For Edge Therapeutics, Inc. (NASDAQ:EDGE)Share Trading News03/08/2016 – Edge Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 24 price target on the stock. 10/26/2015 – Guggenheim began new coverage on Edge Therapeutics, Inc. giving the company a ...and more »
05/20/16 11:31 AMCredit Suisse Maintains Edge Therapeutics Inc to Outperform with Price Target $18.00 - Trade Calls - Credit Suisse Maintains Edge Therapeutics Inc to Outperform with Price Target $18.00Trade CallsBrokerage firm Credit Suisse Maintains its rating on Edge Therapeutics Inc(NASDAQ:EDGE). In a research note issued to the investors, the brokerage major Lowers the price-target to $18.00 per share. The shares have been rated Outperform. The rating by ...Edge Therapeutics, Inc. (NASDAQ:EDGE) Updated Broker Price TargetsShare Trading NewsRecently Changed Price Targets On Edge Therapeutics, Inc. (NASDAQ:EDGE)Risers & Fallersall 35 news articles »

Social

About Edge Therapeutics

Edge Therapeutics logoEdge Therapeutics, Inc. is a clinical-stage biotechnology company. The Company discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening conditions. The Company's product candidates include EG-1962 and EG-1964. The Company's lead product candidate, EG-1962, is initially being developed to improve clinical outcomes following subarachnoid hemorrhage (SAH) by administration through an external ventricular drain (EVD). Its second product candidate, EG-1964, contains aprotinin, a pancreatic trypsin inhibitor initially marketed as Trasylol, and is being developed using its Precisa development platform for the management of chronic subdural hematoma (cSDH), as a prophylactic treatment to prevent recurrent bleeding. Its product candidates utilize its Precisa development platform, which allows the Company to create therapeutics that are based on specific physical and chemical properties.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EDGE
  • CUSIP:
Key Metrics:
  • Previous Close: $9.89
  • 50 Day Moving Average: $9.69
  • 200 Day Moving Average: $8.87
  • P/E Ratio: N/A
  • P/E Growth: -0.08
  • Market Cap: $284.97M
  • Current Year EPS Consensus Estimate: $-1.50 EPS
  • Next Year EPS Consensus Estimate: $-1.49 EPS
Additional Links:
Edge Therapeutics (NASDAQ:EDGE) Chart for Wednesday, July, 27, 2016